for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PPD Inc

PPD.O

Latest Trade

46.11USD

Change

-0.01(-0.02%)

Volume

2,619,869

Today's Range

46.00

 - 

46.15

52 Week Range

24.75

 - 

46.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
46.12
Open
46.14
Volume
2,619,869
3M AVG Volume
71.11
Today's High
46.15
Today's Low
46.00
52 Week High
46.49
52 Week Low
24.75
Shares Out (MIL)
350.98
Market Cap (MIL)
16,187.04
Forward P/E
31.22
Dividend (Yield %)
--

Next Event

Q2 2021 PPD Inc Earnings Release

Latest Developments

More

Ppd Reports Q1 EPS $0.21

Thermo Fisher Nears Deal To Buy PPD For More Than $15 Billion- WSJ

Ppd Posts Q4 Adjusted Earnings Per Share $0.39

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PPD Inc

PPD, Inc. provides drug development services to the biopharmaceutical industry. The Company provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. The Company’s business segments include Clinical Development Services segment and Laboratory Services segment. Its Clinical Development Services offerings span the lifecycle of clinical product development and includes product development and consulting services, early development services, phases II-IV clinical trial management, accelerated enrollment solutions, peri- and post-approval services and medical communications. The Company’s Laboratory Services segment offers bioanalytical laboratory services, biomarker laboratory services, vaccine science services, good manufacturing practice (GMP) laboratory services and central laboratory services.

Industry

Biotechnology & Drugs

Contact Info

929 North Front Street

WILMINGTON, NC

28401-3331

United States

+1.910.2510081

https://www.ppd.com/

Executive Leadership

David S. Simmons

Chairman of the Board, Chief Executive Officer

Christopher G. Scully

Chief Financial Officer, Executive Vice President, Treasurer, Assistant Secretary

William J. Sharbaugh

Chief Operating Officer

Ronald E. Garrow

Chief Human Resource Officer, Executive Vice President

B. Judd Hartman

Executive Vice President, Chief Administrative Officer

Key Stats

3.00 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

4.0K

2020

4.7K

2021(E)

5.5K
EPS (USD)

2019

1.020

2020

1.190

2021(E)

1.477
Price To Earnings (TTM)
136.47
Price To Sales (TTM)
3.46
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
36.14
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
4.56
Return on Equity (TTM)
2.85

Latest News

Latest News

Thermo Fisher expands pharma service business with $17.4 billion PPD acquisition

Medical device maker Thermo Fisher Scientific Inc said on Thursday it would acquire contract researcher PPD Inc for $17.4 billion as it looks to add more muscle to its pharmaceutical services business.

Cravath, Simpson, Arnold & Porter line up for Thermo Fisher's $17.4 bln PPD buy

Cravath, Swaine & Moore and Arnold & Porter Kaye Scholer are guiding medical device maker Thermo Fisher Scientific Inc in its $17.4 billion cash acquisition of drug testing company PPD Inc, which turned to Simpson, Thacher & Bartlett.

Thermo Fisher to buy PPD in $21 billion deal

Thermo Fisher Scientific Inc on Thursday said it would acquire contract research firm PPD Inc for about $20.9 billion, including net debt. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Bernard Orr)

Thermo Fisher in late talks to buy PPD for over $15 billion - WSJ

Medical device company Thermo Fisher Scientific is nearing a deal to buy contract research firm PPD Inc for more than $15 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Thermo Fisher in late talks to buy PPD for over $15 bln - WSJ

Thermo Fisher Scientific is nearing a deal to buy PPD Inc for more than $15 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

BRIEF-PPD Expands Laboratory Test Portfolio For Covid-19 Therapy, Vaccine Development Programs

* PPD EXPANDS LABORATORY TEST PORTFOLIO FOR COVID-19 THERAPY AND VACCINE DEVELOPMENT PROGRAMS Source text for Eikon: Further company coverage:

BRIEF-PPD Announces Pricing And Upsizing Of Senior Notes Offering

* PPD, INC. ANNOUNCES PRICING AND UPSIZING OF SENIOR NOTES OFFERING

BRIEF-PPD Inc Says Intends To Offer $700 Million Senior Notes

* PPD INC - NOTES ARE EXPECTED TO BE ISSUED BY COMPANY'S INDIRECT WHOLLY OWNED SUBSIDIARIES, JAGUAR HOLDING COMPANY II AND PPD DEVELOPMENT, L.P.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up